Trump signs executive order fast-tracking reclassification of marijuana

Former President Trump has proposed new rules that would end gender-related care for minors, threatening hospitals that provide such services with the loss of all federal funding. This move has sparked significant backlash from advocates who anticipate legal challenges against the administration's actions.

President Trump signed an executive order aimed at fast-tracking the reclassification of cannabis, which is currently classified as a Schedule I drug. The order is intended to ease regulatory hurdles for medical research, although it does not legalize cannabis itself.

Novo Nordisk has submitted a request for U.S. FDA approval for CagriSema, a new obesity treatment that combines two compounds into a once-weekly injection. This move follows the success of Wegovy, another obesity drug from the company, which has gained significant attention in the market.

The FDA has approved a label change for Pfizer's birth control shot, Depo-Provera, to include a warning about the risk of meningioma, a type of brain tumor. This decision follows growing concerns regarding the safety of the contraceptive and its potential health implications for users.